Atossa Therapeutics (NASDAQ:ATOS) Earns “Buy” Rating from HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 337.96% from the company’s current price.

Several other equities analysts have also weighed in on ATOS. StockNews.com raised Atossa Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Ascendiant Capital Markets increased their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th.

Atossa Therapeutics Stock Down 2.8 %

Atossa Therapeutics stock traded down $0.04 during trading on Thursday, hitting $1.37. The stock had a trading volume of 230,103 shares, compared to its average volume of 1,086,837. The stock’s 50 day moving average is $1.43 and its two-hundred day moving average is $1.38. Atossa Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.31. The stock has a market cap of $172.29 million, a price-to-earnings ratio of -5.75 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, equities research analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Therapeutics

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its holdings in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares during the period. Cetera Advisors LLC bought a new position in shares of Atossa Therapeutics in the first quarter worth $72,000. Virtu Financial LLC bought a new position in shares of Atossa Therapeutics in the first quarter worth $151,000. Rhumbline Advisers bought a new position in shares of Atossa Therapeutics in the second quarter worth $161,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the period. 12.74% of the stock is owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.